Immunovia AB Stock London S.E.
Stocks
0G8X
SE0006091997
Advanced Medical Equipment & Technology
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.92 SEK | -32.03% |
|
+16,951.28% | +13,658.62% |
| Market Cap | 118M 12.14M 10.65M 9.9M 9.1M 17.1M 1.17B 17.31M 45.96M 575M 45.59M 44.62M 2B | P/E 2026 * |
-1.75x | P/E 2027 * | -4.38x |
|---|---|---|---|---|---|
| Enterprise Value | 50.72M 5.23M 4.59M 4.26M 3.92M 7.37M 505M 7.46M 19.8M 248M 19.64M 19.23M 861M | EV / Sales 2026 * |
15.8x | EV / Sales 2027 * | 2.53x |
| Free-Float |
89.3% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Immunovia AB
| 1 day | -32.03% | ||
| 1 week | +16,951.28% | ||
| Current month | +16,370.59% | ||
| 1 month | +16,806.78% | ||
| 3 months | +15,860.00% | ||
| 6 months | +14,725.82% | ||
| Current year | +13,658.62% |
| 1 week | 0.18 |  | 0.32 |
| 1 month | 0.18 | | 0.32 |
| Current year | 0.15 | | 0.32 |
| 1 year | 0.15 | | 0.92 |
| 3 years | 0.15 | | 2.78 |
| 5 years | 0.15 | | 139.14 |
| 10 years | 0.15 | | 292 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jeff Borcherding
CEO | Chief Executive Officer | 53 | 2023-04-28 |
Lisa Ford
CTO | Chief Tech/Sci/R&D Officer | 55 | 2024-04-28 |
| Chief Tech/Sci/R&D Officer | 54 | 2024-01-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | 2016-12-08 | |
Peter Andersen
CHM | Chairman | 69 | 2023-05-25 |
| Director/Board Member | 51 | 2020-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -32.03% | +16,951.28% | - | - | 12.14M | |
| -0.36% | -9.20% | +15.65% | -38.35% | 15.54B | |
| -7.90% | +5.00% | -2.15% | +84.41% | 1.65B | |
| -3.20% | -7.65% | -41.40% | -81.89% | 1.09B | |
| -1.41% | -4.66% | -38.57% | +10.83% | 948M | |
| -3.39% | -5.61% | -45.48% | -55.93% | 609M | |
| -2.46% | -5.34% | -51.05% | -58.53% | 505M | |
| +1.87% | +3.51% | +39.11% | -52.08% | 460M | |
| +1.52% | -3.98% | -57.46% | -61.30% | 365M | |
| +0.72% | -4.89% | -22.14% | -37.78% | 344M | |
| Average | -4.66% | -3.58% | -22.61% | -32.29% | 2.39B | |
| Weighted average by Cap. | -1.18% | -7.28% | +4.35% | -30.65% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.2M 330K 290K 269K 247K 465K 31.89M 471K 1.25M 15.63M 1.24M 1.21M 54.34M | 17.3M 1.78M 1.57M 1.45M 1.34M 2.51M 172M 2.54M 6.75M 84.52M 6.7M 6.56M 294M |
| Net income | -91M -9.39M -8.23M -7.65M -7.03M -13.22M -907M -13.38M -35.53M -445M -35.24M -34.5M -1.55B | -82M -8.46M -7.42M -6.89M -6.34M -11.91M -817M -12.06M -32.02M -401M -31.76M -31.08M -1.39B |
| Net Debt | -67M -6.91M -6.06M -5.63M -5.18M -9.74M -668M -9.85M -26.16M -327M -25.95M -25.4M -1.14B | -74M -7.63M -6.7M -6.22M -5.72M -10.75M -737M -10.88M -28.89M -362M -28.66M -28.05M -1.26B |
Employees
17
Calendar
Aug. 05
Earnings release - Q2 2026
| Date | Price | Change | Volume |
|---|
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- IMMNOV Stock
- 0G8X Stock
Select your edition
All financial news and data tailored to specific country editions
